10147-69-0

Basic information

• Product Name: 2-CHLORO-N-(3-HYDROXY-PHENYL)-ACETAMIDE
• Synonyms: 2-CHLORO-N-(3-HYDROXY-PHENYL)-ACETAMIDE;2'-CHLORO-3-HYDROXYACETANILIDE;2-chloro-N-(3-hydroxyphenyl)ethanamide;Acetamide, 2-chloro-N-(3-hydroxyphenyl)-
• CAS NO: 10147-69-0
• Molecular Formula: C₈H₈ClNO₂
• Molecular Weight: 185.61
• Mol File: 10147-69-0.mol

Chemical Properties

• Boiling Point: 414.4 °C at 760 mmHg
• Flash Point: 204.4 °C
• Appearance: /
• Density: 1.402 g/cm³
• Vapor Pressure: 1.86E-07mmHg at 25°C
• Refractive Index: 1.632
• CAS DataBase Reference: 2-CHLORO-N-(3-HYDROXY-PHENYL)-ACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLORO-N-(3-HYDROXY-PHENYL)-ACETAMIDE(10147-69-0)
• EPA Substance Registry System: 2-CHLORO-N-(3-HYDROXY-PHENYL)-ACETAMIDE(10147-69-0)

Safety Data

• Hazardous Substances Data: 10147-69-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-CHLORO-N-(3-HYDROXY-PHENYL)-ACETAMIDE is used as a muscle relaxant for the treatment of muscle spasms and discomfort caused by injuries. It is particularly effective in conditions such as cerebral palsy, multiple sclerosis, and stroke, where muscle tension and spasms can significantly impact the quality of life.
Used in Medical Treatments:
As a centrally-acting agent, 2-CHLORO-N-(3-HYDROXY-PHENYL)-ACETAMIDE is utilized to alleviate muscle-related symptoms that can accompany various medical conditions. Its muscle-relaxing properties make it a valuable component in the therapeutic approach to managing the physical manifestations of these conditions.
Used in Oral Tablet Form:
2-CHLORO-N-(3-HYDROXY-PHENYL)-ACETAMIDE is available in an oral tablet form, making it a convenient and accessible treatment option for patients. This form of administration allows for easy dosage control and patient compliance.
Used for Temporary Relief:
While 2-CHLORO-N-(3-HYDROXY-PHENYL)-ACETAMIDE is generally well-tolerated, it may cause side effects such as drowsiness, dizziness, or nausea. It is typically used for temporary relief of muscle symptoms, with the understanding that long-term use may require monitoring and consideration of potential side effects.
Overall, 2-CHLORO-N-(3-HYDROXY-PHENYL)-ACETAMIDE is an important pharmaceutical compound that serves a crucial role in the management and treatment of muscle-related conditions across various medical applications.

InChI:InChI=1/C8H8ClNO2/c9-5-8(12)10-6-2-1-3-7(11)4-6/h1-4,11H,5H2,(H,10,12)

Upstream product

• 591-27-5 m-Hydroxyaniline 
• 541-88-8 Chloroacetic anhydride 
• 79-04-9 chloroacetyl chloride 

Downstream Products

• 51964-26-2 3-(3-hydroxy-phenyl)-thiazolidine-2,4-dione 
• 1182347-19-8 diethyl [N-(3-hydroxyphenyl)carbamoyl]methylphosphonate 
• 916337-42-3 C₁₀H₁₂ClNO₃ 

Relevant articles and documents

Thiazolidine-2,4-dione-based irreversible allosteric IKK-β kinase inhibitors: Optimization into in vivo active anti-inflammatory agents

Selective kinase inhibitors development is a cumbersome task because of ATP binding sites similarities across kinases. On contrast, irreversible allosteric covalent inhibition offers opportunity to develop novel selective kinase inhibitors. Previously, we

Synthesis, In Vitro Biological Screening, and In Silico Computational Studies of Some Novel Imidazole-2-thiol Derivatives

Substituted imidazole analogues 2-((5-acetyl-4-methyl-1-phenyl-1H-imidazole-2-yl)thio)-N-phenylacetamides (3a–3m) have been synthesized from 1-[1-(phenyl)-2-mercapto-4-methyl-1H-imidazol-5-yl]-ethanone (1a–1e) and 2-chloro-N-phenylacetamide (2a–2i) in the

A highly selective and sensitive fluorescent chemosensor for Fe 3+ in physiological aqueous solution

A novel fluorescent chemosensor in which two aza-18-crown-6 moieties are linked to a coumarin fluorophore has been synthesized for sensing Fe 3+. The selective fluorescence enhancement was observed upon binding Fe3+ at physiological

Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and Stimulator for Interferon Genes (STING) modulators as cancer immunotherapeutics

Substituted -3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and related compounds, which are useful as inhibitors of ENPP1; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds and compositions to treat disorders associated with dysfunction of the ENPP1.

Antidiabetic compounds

Compounds for the treatment of hyperglycemia and/or diabetes are provided. The compounds, which inhibit the enzyme dipeptidyl peptidase (DPP-4), are based on the structure where X may be present or absent an may be OH, Ar is an aryl group; and n ranges from 0 to 5.

Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and Stimulator for Interferon Genes (STING) modulators as cancer immunotherapeutics

Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and related compounds, which are useful as inhibitors of ENPP1; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds and compositions to treat disorders associated with dysfunction of the ENPP1.

Exploring DOXP-reductoisomerase binding limits using phosphonated N-aryl and N-heteroarylcarboxamides as DXR inhibitors

DOXP-reductoisomerase (DXR) is a validated target for the development of antimalarial drugs to address the increase in resistant strains of Plasmodium falciparum. Series of aryl- and heteroarylcarbamoylphosphonic acids, their diethyl esters and disodium salts have been prepared as analogues of the potent DXR inhibitor fosmidomycin. The effects of the carboxamide N-substituents and the length of the methylene linker have been explored using in silico docking studies, saturation transfer difference NMR spectroscopy and enzyme inhibition assays using both EcDXR and PfDXR. These studies indicate an optimal linker length of two methylene units and have confirmed the importance of an additional binding pocket in the PfDXR active site. Insights into the constraints of the PfDXR binding site provide additional scope for the rational design of DXR inhibitors with increased ligand-receptor interactions.

3-substituted anilines as scaffolds for the construction of glutamine synthetase and DXP-reductoisomerase inhibitors

Access to a series of truncated ATP analogs, as potential anti-tuberculosis agents, has been explored via alkylation and acylation of 3-aminophenol, whereas chloroacetylation, using chloroacetyl chloride, and subsequent Arbuzov phosphonation of a series of 3-substituted anilines have afforded a series of phosphonate derivatives as potential antimalarial agents.